cyproterone acetate has been researched along with Invasiveness, Neoplasm in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bono, AV; Brausi, M; Calais da Silva, FE; Calais da Silva, FM; Kirkali, Z; Marques Queimadelos, A; Martin, JA; Robertson, C; Whelan, P | 1 |
| Bernier, J; Billiet, I; Bolla, M; Collette, L; Cutajar, CL; Dubois, JB; Kuten, A; Mirimanoff, RO; Pfeffer, R; Sternberg, C; Storme, G; Torecilla, JL; Van der Kwast, T; Van Tienhoven, G; Warde, P | 1 |
| D'Amico, AV | 1 |
2 trial(s) available for cyproterone acetate and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cyproterone Acetate; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Gonadotropin-Releasing Hormone; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Assessment; Survival Analysis | 2009 |
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Canada; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Europe; Fractures, Bone; Goserelin; Humans; Israel; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Prostatic Neoplasms; Risk Assessment; Russia; Time Factors; Treatment Outcome | 2010 |
1 other study(ies) available for cyproterone acetate and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Is long-term androgen suppression right for everyone with locally advanced prostate cancer?
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Fractures, Bone; Goserelin; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Prostatic Neoplasms; Risk Assessment; Time Factors; Treatment Outcome | 2010 |